Literature DB >> 33481068

High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.

Payel Datta1, Li Fu1, Paul Brodfuerer1, Jonathan S Dordick2,3, Robert J Linhardt4,5,6.   

Abstract

Heparosan is a naturally occurring non-sulfated glycosaminoglycan. Heparosan serves as the substrate for chemoenzymatic synthesis of biopharmaceutically important heparan sulfate and heparin. Heparosan is biologically inert molecule, non-toxic, and non-immunogenic and these qualities of heparosan make it an ideal drug delivery vehicle. The critical-to-quality (CTQ) attributes for heparosan applications include composition of heparosan, absence of any unnatural moieties, and heparosan molecular weight size and unimodal distribution. Probiotic bacteria E. coli Nissle 1917 (EcN) is a natural producer of heparosan. The current work explores production of EcN heparosan and process parameters that may impact the heparosan CTQ attributes. Results show that EcN could be grown to high cell densities (OD600 160-180) in a chemically defined media. The fermentation process is successfully scaled from 5-L to 100-L bioreactor. The chemical composition of heparosan from EcN was confirmed using nuclear magnetic resonance. Results demonstrate that heparosan molecular weight distribution may be influenced by fermentation and purification conditions. Size exclusion chromatography analysis shows that the heparosan purified from fermentation broth results in bimodal distribution, and cell-free supernatant results in unimodal distribution (average molecular weight 68,000 Da). The yield of EcN-derived heparosan was 3 g/L of cell free supernatant. We further evaluated the application of Nissle 1917 heparosan for chemical modification to prepare N-sulfo heparosan (NSH), the first intermediate precursor for heparin and heparan sulfate. KEY POINTS: • High cell density fermentation, using a chemically defined fermentation media for the growth of probiotic bacteria EcN (E. coli Nissle 1917, a natural producer of heparosan) is reported. • Process parameters towards the production of monodispersed heparosan using probiotic bacteria EcN (Nissle 1917) has been explored and discussed. • The media composition and the protocol (SOPs and batch records) have been successfully transferred to contract manufacturing facilities and industrial partners.

Entities:  

Keywords:  Chemoenzymatic modifications; E. coli K5; E. coli Nissle 1917; EcN; Fed-batch fermentation; Heparan sulfate; Heparin; Heparin lyase; Heparosan; High cell density fed-batch fermentation; N-sulfo heparosan; Probiotic Nissle 1917

Mesh:

Substances:

Year:  2021        PMID: 33481068     DOI: 10.1007/s00253-020-11079-9

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  32 in total

1.  Identification and molecular cloning of a heparosan synthase from Pasteurella multocida type D.

Authors:  Paul L DeAngelis; Carissa L White
Journal:  J Biol Chem       Date:  2001-12-26       Impact factor: 5.157

2.  Generation of "neoheparin" from E. coli K5 capsular polysaccharide.

Authors:  Ulf Lindahl; Jin-Ping Li; Marion Kusche-Gullberg; Markku Salmivirta; Sakari Alaranta; Timo Veromaa; Jef Emeis; Ian Roberts; Clare Taylor; Pasqua Oreste; Giorgio Zoppetti; Annamaria Naggi; Giangiacomo Torri; Benito Casu
Journal:  J Med Chem       Date:  2005-01-27       Impact factor: 7.446

3.  The JUMPstart sequence: a 39 bp element common to several polysaccharide gene clusters.

Authors:  M Hobbs; P R Reeves
Journal:  Mol Microbiol       Date:  1994-06       Impact factor: 3.501

4.  Metabolic engineering of Bacillus subtilis for biosynthesis of heparosan using heparosan synthase from Pasteurella multocida, PmHS1.

Authors:  Xiaofei Chen; Rong Chen; Xiaoxiao Yu; Dongyang Tang; Wenbing Yao; Xiangdong Gao
Journal:  Bioprocess Biosyst Eng       Date:  2017-01-24       Impact factor: 3.210

5.  SlyA and H-NS regulate transcription of the Escherichia coli K5 capsule gene cluster, and expression of slyA in Escherichia coli is temperature-dependent, positively autoregulated, and independent of H-NS.

Authors:  David Corbett; Hayley J Bennett; Hamdia Askar; Jeffrey Green; Ian S Roberts
Journal:  J Biol Chem       Date:  2007-09-07       Impact factor: 5.157

6.  Enzymatic Generation of Highly Anticoagulant Bovine Intestinal Heparin.

Authors:  Li Fu; Kevin Li; Daisuke Mori; Makoto Hirakane; Lei Lin; Navdeep Grover; Payel Datta; Yanlei Yu; Jing Zhao; Fuming Zhang; Murat Yalcin; Shaker A Mousa; Jonathan S Dordick; Robert J Linhardt
Journal:  J Med Chem       Date:  2017-10-16       Impact factor: 7.446

7.  Bioengineered Chinese hamster ovary cells with Golgi-targeted 3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site.

Authors:  Payel Datta; Guoyun Li; Bo Yang; Xue Zhao; Jong Youn Baik; Trent R Gemmill; Susan T Sharfstein; Robert J Linhardt
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

8.  Recombinant Escherichia coli K5 strain with the deletion of waaR gene decreases the molecular weight of the heparosan capsular polysaccharide.

Authors:  Haichan Huang; Xiaobo Liu; Shencong Lv; Weihong Zhong; Fuming Zhang; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2016-04-14       Impact factor: 4.813

Review 9.  Bioengineered heparins and heparan sulfates.

Authors:  Li Fu; Matthew Suflita; Robert J Linhardt
Journal:  Adv Drug Deliv Rev       Date:  2015-11-10       Impact factor: 15.470

10.  Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.

Authors:  So Young Kim; Weihua Jin; Amika Sood; David W Montgomery; Oliver C Grant; Mark M Fuster; Li Fu; Jonathan S Dordick; Robert J Woods; Fuming Zhang; Robert J Linhardt
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.